Natco Pharma ventures into Pheromone based technology for Integrated Pest Management

Published On 2021-03-16 06:45 GMT | Update On 2021-03-16 10:27 GMT

Hyderabad: Natco Pharma Limited has recently announced that the company ventured into Pheromone based mating disruption technology for Integrated Pest Management (IPM) solution to farmers in India.

NATCO through its Crop Health Science (CHS) division is working with ATGC Biotech Pvt Ltd (ATGC) for the technology.

ATGC is a science based innovative technology company concentrating on developing new biosafe molecules and tools to protect diverse crops from insect pests, in collaboration with US based agricultural biotech company ISCA Inc.

During Kharif 2021, NATCO plans to launch its first Green Label Pheromone product for Effective Management of Pink Bollworm (PBW) in cotton crop, under its brand NATMATE PBW. This is the first pheromone-based indigenously manufactured product for mating disruption that received approval from Central Insecticide Board (CIB). With this launch, cotton farmers will have a new and powerful tool to manage PBW.

Pink Bollworm posed a major challenge in the past few years to cotton farmers across India. The damage to quality and yield of cotton due to PBW is significant and often severely affects the livelihood of small farmers. Now, NATMATE PBW will be a tool in the hands of farmers and seed producers in developing an Insect Resistance Management (IRM) plan and preserve benefits of Bt traits in cotton as well.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Natco Pharma ventures into Pheromone based technology for Integrated Pest Management

Similar News

Pfizer's Abrocitinib Phase III Data Accepted by CDSCO Expert Committee

COVID-19 Vaccine and Heart Attack: Biocon Chief, Karnataka CM get into war of words

Govt Panel Makes This Approval Mandatory For New Drug Licenses

CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore